Strides Pharma Science receives approval for Rx, OTC Ranitidine tablets

25 Sep 2019 Evaluate

Strides Pharma Science has received an approval from US Food and Drug Administration (USFDA) for Rx and OTC Ranitidine tablets for the US market and is only commercializing the Rx product currently.

The USFDA has learned that some ranitidine products contain a nitrosamine impurity called N-nitrosodimethylamine (NDMA) at low levels. NDMA is also found in water and  foods,  including meats,  dairy  products,  and  vegetables  and  is  not  expected  to cause harm when ingested in very low levels. USFDA is not calling for individuals to stop taking ranitidine at this time. The agency is examining the levels of NDMA in ranitidine and is evaluating any possible risks to patients. Basis a Citizen petition, the USFDA is now reaching out to all formulation companies to perform tests to evaluate presence of NDMA in the product.

The company has also received an Information Request (IR) from USFDA to provide test data in next 30 days. The  company  is  in  the  process  of  responding  to  the  IR comprehensively. Further updates on the product will be provided post completion of the requisite tests.  Ranitidine tablets is amongst the top 5 products sold by the company in the USA.

Strides Pharma Science (Formerly Strides Shasun) is a pharmaceutical company with a major focus on development and manufacture of IP-led niche finished dosage formulations. It is also among the world’s largest manufacturers of soft gelatin capsules.

Strides Pharma Scien Share Price

882.75 -8.20 (-0.92%)
12-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1794.30
Dr. Reddys Lab 1279.65
Cipla 1517.20
Zydus Lifesciences 929.05
Lupin 2114.10
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×